Skip to main content

Swiss-US trade relations

Following the lifting of the country-specific additional tariffs by the US Supreme Court, the US President introduced a new across-the-board additional tariff of 10% citing a different legal basis. This across-the-board additional tariff is to be levied on all trading partners and is in addition to the applicable Most Favoured Nation tariffs. Certain products listed in Annex II of the Executive Order remain exempt from the additional tariffs. Existing sector-specific additional tariffs remain payable. From 31 July 2026, additional tariffs will be imposed on pharmaceutical products under Section 232.

An American flag and a Swiss flag

Information and points of contact for affected businesses

Official information from the US government

As of 2 April 2026

On 20 February, the US Supreme Court ruled that the International Emergency Economic Powers Act (IEEPA) does not authorise the US President to impose general tariffs. The court thereby overturned the government's application of this law to justify the imposition of comprehensive additional tariffs on imports since 2 April 2025.

Nevertheless, the US government is firmly pursuing its approach to trade and economic policy. Shortly after the ruling was announced, it decided to replace the IEEPA-based tariffs with new additional tariffs based on different legislation. These came into force on 24 February.

The new additional tariffs under Section 122 of the US Trade Act will not be applied in addition to the existing country-specific additional tariffs but will replace them for a period of 150 days. They are to be applied in addition to the most-favoured-nation tariffs already in place prior to 2 April 2025. The US administration has announced that it is preparing trade measures based on different legislation, which are intended to replace the Section 122 tariffs once the 150-day period expires. At the same time, it signalled its intention to respect existing trade agreements – such as those with Switzerland – during implementation.

On 2 April 2026, the US President also announced new Section 232 tariffs on pharmaceutical products. An additional duty of up to 15% is to be levied on US pharmaceutical imports from Switzerland. However, there are various product exemptions and company-specific regulations that allow for the import of pharmaceuticals at reduced or zero additional tariffs. The US is thus adhering to the joint memorandum of understanding of 14 November 2025. At the same time, an adjustment to the existing Section 232 additional tariffs on steel, aluminium and copper was announced. Negotiations on a trade agreement with the US are continuing. Under the current negotiating mandate, the aim of the ongoing negotiations remains to secure stable conditions for Swiss businesses in the US market and to improve these where possible.

SECO will keep the affected industries informed about the application of the new regulations and the corresponding customs tariffs.

Questions and answers

The provision of binding legal information on US import regulations and tariffs is the responsibility of the relevant US authorities (see contact details for U.S. Customs and Border Protection). The information provided here is for information purposes only.

Press releases

Contact

State Secretariat for Economic Affairs SECO
Foreign Economic Affairs Directorate
Bilateral Economic Relations Americas
Holzikofenweg 36
CH - 3003 Bern